BioNTech CEO: China may approve BioNTech’s COVID-19 vaccine in July
- Did Cloud Seeding Unleash a Deluge in Dubai?
- Scientists Identify Gut Bacteria and Metabolites that Lower Diabetes Risk
- OpenAI’s Model Matches Doctors in Assessing Eye Conditions
- UK: A Smoke-Free Generation by Banning Sales to Those Born After 2009
- Deadly Mutation: A New Monkeypox Variant Emerges in the DRC
- EPA Announces First-Ever Regulation for “Forever Chemicals” in Drinking Water
BioNTech CEO: China may approve BioNTech’s COVID-19 vaccine in July
BioNTech CEO: China may approve BioNTech’s COVID-19 vaccine in July. Bloomberg reported on April 28 that BioNTech CEO Ugur Sahin said at a press conference that the company is responding to some final questions from Chinese regulators in order to obtain China’s approval of its COVID-19 vaccine. According to the report, Sahin believes that China may approve the BioNTech vaccine in July.
According to a report in the English version of the Global Times on the 22nd, sources revealed that China is likely to approve the COVID-19 vaccine jointly developed by BioNTech and China Fosun Pharmaceutical before July. Preparations for vaccine production plants and cold chain distribution exercises are underway. . According to the report, once the vaccine is authorized, it will be quickly launched in the mainland, because the key steps of mass production are almost complete.
In December last year, Fosun Pharma issued an announcement on the Hong Kong Stock Exchange stating that the board of directors announced that on December 15, 2020, BioNTech’s subsidiaries BioNTech Manufacturing, Fosun Pharmaceutical Industries and BioNTech will supply them with COVID-19 in Mainland China regarding BioNTech Manufacturing. Vaccine products entered into a supply agreement.
According to the supply agreement, BioNTech Manufacturing promised to supply no less than 100 million doses of COVID-19 vaccine products to mainland China in 2021 when the COVID-19 vaccine product was approved for marketing in Mainland China and Fosun Pharmaceuticals placed corresponding orders in accordance with the supply agreement. The report pointed out that this vaccine is called BNT162b2, which is expected to become the first foreign developed vaccine imported from mainland China.
Other news: Probably need the third shot
Pfizer and BioNTech vaccinators are expected to receive the third dose within 9 to 12 months after the first dose, so that the effective rate of the vaccine can be restored to close to 100%.
For Pfizer vaccinators, it is more likely that in the future, they will need another booster shot every 12 or 18 months to improve their effectiveness.
Ugur Sahin, the founder and CEO of German biotechnology company BioNTech, said that data from people who have been vaccinated with the COVID-19 vaccine show that the COVID-19 vaccine developed by BioNTech and produced by Pfizer will be effective in half a year from the original 95 % Dropped to about 91%, and the immune response was weakened, so a third injection is needed to make the vaccine protective and return to nearly 100% again.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
